Researchers report that an experimental peptide-based drug reversed myelin damage in a mouse model of multiple sclerosis, suggesting a possible repair-focused therapy. The findings come from preclinical work, and human trials have not yet begun. The approach is moving toward clinical translation.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.